Psoriasisde kalsipotriol ile betametazon-17 valeratın etkinliğinin karşılaştırılması

Amaç: Çalışmamızda psoriasis vulgaris tedavisinde kalsipotriol merhem ile betametazon 17-valerat merhem tedavisinin etkinliği, tolere edilebilirliği ve emniyeti karşılaştırmalı olarak değerlendirildi. Yöntem: Hastaların sağ vücut yarısına betametazon 17-valerat merhem günde 2 kez uygulandı. Aynı hastaların sol vücut yarısına kalsipotriol merhem günde 2 kez ugulandı. Çalışma 6 hafta sürdü. Bulgular: Tedavi sonunda iki ilacın PASI (psöriasis alan ağırlık indeksi) skorunu azaltmaya olan etkileri arasındaki fark istatistiksel olarak anlamlı bulunmadı. Sonuç: Her iki tedavi de iyi tolere edildi.

Comparative effects of calcipotriol ointment and betametasone-17 valerate ointment in the treatment of psoriasis

Objective: In our study, the efficacy, tolerability and safety of calcipotriol ointment were compared with betamethasone 17- valerate ointment. Methods: Betamethasone 17- valerate ointment was applied twice daily to the right side of the patients' bodies. Calcipotriol ointment was applied twice daily to the left side of the same patients' bodies. This study has been continued for 6 weeks. Results: The difference of the decrease in PASII (Psoriasis Area Severity Index) was not statistically significant between the two treatment modalities. Conclusion: Both treatments were well tolerated.

___

  • 1. Brandrup F,Green A.The prevalence of psoriasis in Denmark Acta Derm Venerol 1981;61:344-6.
  • 2. Camisa C. Psoriasis. 1 st ed. Blackwell Scietific Publications, London 1994:1-30.
  • 3. Kaiser H,Kley HK.Cortison derivate in clinic and praxis.1993:360.
  • 4. Bolduc A,Boucier M,Nault P,Ramsay CA,Schwartz BE.Calcipotriol combined with twice weekly UVB phototherapy:a safe,effective and UVB-sparing anti-psoriatic treatment.JEADV 1999;12(2):S328.
  • 5. Kragbelle K,Gjertsen BT.Double-blind right/left comparison of calcipotriol and betametasone valerate in treatment of psoriasis vulgaris.Lancet 1991;337:193-6.
  • 6. Berritsen MJP,Rulo HFC,Von Wlijman-Williens I,Von Erp PEJ,Von de Kerkhof PCM.Topical treatment of psoriatic plaques with 1,25 dihydroxy vitamin D 3 ; A cell biolocical study.Br J Dermatol 1993;128:666-73.
  • 7. Kragbelle K,Beck HI,Sogaard H.Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind study.Br J Dermatol 1988;119:223-30.
  • 8. Staberg B, Roed-Petersen J, Menne T.Efficacy of topical treatment in psoriasis with MC 903 a new vitamin D analogue. Acta Drem Venerel 1989;69:147-50.
  • 9. Kundakçı N,Erdi H,Taşpınar A.Psoriazis vulgaris tedavisinde calcipotriol merhem ve cignolin merhem tedavisinin karşılaştırmalı değerlendirilmesi.Türk Klin Dermatol 1995;5(3):129-34.
  • 10. Klaber MR.Comparative effects of calcipotriol solution (50 m g/m) and betamethasone 17- valerate solution (1 mg/ml) in the treatment of scalp psoriasis .Br J Dermatol 1994;131:678-83.
  • 11. Kragbelle K,Steijlen PM,Ibsen HH,Vade Kerkhof PMC, Esmann J, Serensen LH, Axelsen MB. Efficacy, tolerability and safety of calcipotriol ointment in disorders of keratinisation.Arch Dermatol 1995;131:556-60.
  • 12. Bert-Jones J,Hutchinson PE.Vitamin D analogues and psoriasis.Br J Dermatol 1992;127:72-8.
  • 13. Cunliffe WJ.Comparative study of calcipotriol (MC 903) ointment and betamethasone 17- valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26:736-43.
  • 14. Tüzün Y,Kotoğyan A,Saylan T.Dermatoloji. İstanbul, İstanbul Matbaası, 1985:347-67.
  • 15. Provost T,Farmer E.Current therapy in dermatology 1988:1-5.
  • 16. Rotsteinn H, Baker C. The treatment of psoriasis.Med J Austr 1990;152-64.